Home Cart Sign in  
Chemical Structure| 35486-42-1 Chemical Structure| 35486-42-1

Structure of 35486-42-1

Chemical Structure| 35486-42-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 35486-42-1 ]

CAS No. :35486-42-1
Formula : C5H4Br2N2
M.W : 251.91
SMILES Code : NC1=NC=C(Br)C=C1Br
MDL No. :MFCD00038041
InChI Key :WJMJWMSWJSACSN-UHFFFAOYSA-N
Pubchem ID :98851

Safety of [ 35486-42-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317-H319
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 35486-42-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 44.04
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

38.91 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.96
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.89
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.2
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.76
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.06
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.97

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.09
Solubility 0.207 mg/ml ; 0.000821 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.33
Solubility 1.18 mg/ml ; 0.00468 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.38
Solubility 0.106 mg/ml ; 0.000422 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.49 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.71

Application In Synthesis of [ 35486-42-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 35486-42-1 ]

[ 35486-42-1 ] Synthesis Path-Downstream   1~9

  • 1
  • [ 35486-42-1 ]
  • [ 13472-81-6 ]
  • [ 40360-47-2 ]
  • 2
  • [ 35486-42-1 ]
  • [ 610261-34-2 ]
  • 5
  • [ 75806-85-8 ]
  • ammonium hydroxide [ No CAS ]
  • [ 35486-42-1 ]
  • 6
  • [ 35486-42-1 ]
  • [ 7664-93-9 ]
  • H2SO5 [ No CAS ]
  • [ 610261-34-2 ]
  • 7
  • [ 35486-42-1 ]
  • [ 12775-96-1 ]
  • [ 39903-01-0 ]
YieldReaction ConditionsOperation in experiment
With potassium hydroxide; In tetrahydrofuran; water; ethyl acetate; EXAMPLE 4 A mixture of 6.5 parts of 2-amino-3,5-dibromopyridine, 12 parts of potassium hydroxide (85percent), 0.5 part of copper powder and 100 parts of water is stirred under nitrogen in an autoclave for 10 hours at 170° C. The dark-coloured solution is neutralised with concentrated hydrochloric acid, saturated with sodium chloride and extracted three times in the warm state with an ethyl acetate/tetrahydrofuran mixture (9:1). The combined organic extracts are filtered through Hyflo, dried with sodium sulphate and filtered. After the solvent has been evaporated off, the residue is taken up in a small amount of hot ethyl acetate and chromatographed through silica gel. After removal of the ethyl acetate, there are obtained 2.2 parts (46.3percent of theory) of 2-amino-3-hydroxy-5-bromopyridine, m.p. 205°-208° C.
  • 8
  • [ 35486-42-1 ]
  • [ 74205-82-6 ]
  • [ 1204587-13-2 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 35486-42-1 ]

Bromides

Chemical Structure| 13534-99-1

A157025 [13534-99-1]

2-Amino-3-bromopyridine

Similarity: 0.88

Chemical Structure| 3430-29-3

A176683 [3430-29-3]

3,5-Dibromo-4-methylpyridin-2-amine

Similarity: 0.88

Chemical Structure| 91872-10-5

A741853 [91872-10-5]

3,5-Dibromo-6-methyl-2-pyridinamine

Similarity: 0.88

Chemical Structure| 1072-97-5

A216085 [1072-97-5]

5-Bromopyridin-2-amine

Similarity: 0.81

Chemical Structure| 896160-69-3

A768078 [896160-69-3]

3-Bromopyridine-2,5-diamine

Similarity: 0.81

Amines

Chemical Structure| 13534-99-1

A157025 [13534-99-1]

2-Amino-3-bromopyridine

Similarity: 0.88

Chemical Structure| 3430-29-3

A176683 [3430-29-3]

3,5-Dibromo-4-methylpyridin-2-amine

Similarity: 0.88

Chemical Structure| 91872-10-5

A741853 [91872-10-5]

3,5-Dibromo-6-methyl-2-pyridinamine

Similarity: 0.88

Chemical Structure| 1072-97-5

A216085 [1072-97-5]

5-Bromopyridin-2-amine

Similarity: 0.81

Chemical Structure| 896160-69-3

A768078 [896160-69-3]

3-Bromopyridine-2,5-diamine

Similarity: 0.81

Related Parent Nucleus of
[ 35486-42-1 ]

Pyridines

Chemical Structure| 13534-99-1

A157025 [13534-99-1]

2-Amino-3-bromopyridine

Similarity: 0.88

Chemical Structure| 3430-29-3

A176683 [3430-29-3]

3,5-Dibromo-4-methylpyridin-2-amine

Similarity: 0.88

Chemical Structure| 91872-10-5

A741853 [91872-10-5]

3,5-Dibromo-6-methyl-2-pyridinamine

Similarity: 0.88

Chemical Structure| 1072-97-5

A216085 [1072-97-5]

5-Bromopyridin-2-amine

Similarity: 0.81

Chemical Structure| 896160-69-3

A768078 [896160-69-3]

3-Bromopyridine-2,5-diamine

Similarity: 0.81